Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 12
Durvalumab in Endometrial Cancer: DUO-E Trial Updates
Panelists discuss recent updates from the DUO-E trial, highlighting key efficacy and safety data that led to the FDA’s approval of durvalumab for endometrial cancer while examining how this new indication influences treatment strategies for advanced or recurrent cases.
Video Player is loading.
Video content above is prompted by the following:
- Briefly comment on recent data updates presented for the DUO-E trial and offer insights into the recently approved FDA indication for durvalumab in endometrial cancer.
- Briefly comment on key takeaways from efficacy and safety data leading to the new approval.
- How does the approved indication for durvalumab affect your treatment approach for advanced or recurrent endometrial cancer?
